Higgs Paul, Murray Jane K, Hibbert Angie
School of Veterinary Sciences, University of Bristol, Langford, Bristol, UK
School of Veterinary Sciences, University of Bristol, Langford, Bristol, UK.
J Feline Med Surg. 2014 Oct;16(10):788-95. doi: 10.1177/1098612X13519633. Epub 2014 Jan 14.
Feline hyperthyroidism is commonly diagnosed in general practice. This study assessed the opinions and experiences of UK general practitioners (GPs) regarding the management of feline hyperthyroidism. This included an evaluation of preferred treatment modalities and the monitoring of medically treated cats in relation to thyroxine (T4) level, co-morbid disease and adverse drug reactions. Six hundred and three GPs completed an online questionnaire comprising 34 questions. Oral medication was the most commonly preferred treatment option (65.7% of respondents), followed by thyroidectomy (27.5%) and then radioiodine (5.5%). When cost of treatment was eliminated as a consideration factor, significantly more respondents selected radioiodine (40.5%, P <0.001). Concerning target total T4 levels during medical management, 48.4% aimed for the lower half of the reference interval (RI), 32.3% anywhere within RI, 13.1% within the top half of RI and 0.5% above the RI; 3.4% evaluated efficacy by physical assessment only. In the presence of chronic kidney disease (CKD) respondents were significantly more likely to target total T4 levels within the upper half of the RI (40.3%) or above it (9.8%) when compared with targets for routine cases (P <0.001). Assessment for unmasking of CKD after initiating treatment or for hypertension was not consistently performed. Variability in monitoring strategies may result in CKD and hypertension remaining undetected, inadequate suppression of T4 levels in cats with concurrent CKD and delayed recognition of potentially significant haematological abnormalities.
猫甲状腺功能亢进症在普通临床实践中很常见。本研究评估了英国全科医生(GP)对猫甲状腺功能亢进症管理的意见和经验。这包括对首选治疗方式以及接受药物治疗的猫在甲状腺素(T4)水平、合并疾病和药物不良反应方面的监测情况的评估。603名全科医生完成了一份包含34个问题的在线问卷。口服药物是最常被首选的治疗选择(65.7%的受访者),其次是甲状腺切除术(27.5%),然后是放射性碘治疗(5.5%)。当不考虑治疗费用时,选择放射性碘治疗的受访者显著增多(40.5%,P<0.001)。关于药物治疗期间的目标总T4水平,48.4%的人目标是参考区间(RI)的下半部分,32.3%的人目标是RI内的任何位置,13.1%的人目标是RI的上半部分,0.5%的人目标是高于RI;3.4%的人仅通过体格检查评估疗效。与常规病例的目标相比,在存在慢性肾脏病(CKD)的情况下,受访者更有可能将总T4水平目标设定在RI的上半部分(40.3%)或更高(9.8%)(P<0.001)。在开始治疗后未持续进行CKD或高血压的筛查评估。监测策略的差异可能导致CKD和高血压未被发现、合并CKD的猫T4水平抑制不足以及潜在的严重血液学异常未被及时识别。